The US Food and Drug Administration looks to receive more information on cannabidiol safety by allowing proprietary data submitted on specific products to remain confidential.
Confidentiality For Proprietary Information Drives FDA Plan To Generate More CBD Safety Data
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."
